We are excited to share the recent interview of CH media to our CEO and CSO Prof. Dario Neri! linkedin.com/posts/philogen…

Thrilled to share another article published by CHEMIEXTRA on Philogen science. Follow the link to learn more about Machine Learning models applied to our DNA Encoded Chemical Library Technology. chemiextra.com/neue-niedermol…

Delighted to invite you to our Webinar on 2 October 2023 to discuss the Company’s Half Year 2023 Results on 2 October 2023 at 10:00 ET / 15:00 BST / 16:00 CET.  Following the link below to register to the event: us06web.zoom.us/webinar/regist…

Phiogen is delighted to share the Half Year 2023 Financial Results. The company will host a Webinar to present the results on 2 October 2023 at 10:00 ET / 15:00 BST / 16:00 CET. Follow the link here shorturl.at/JM178 to register to the event or contact [email protected]

Philogen is delighted to share the Half Year 2023 Financial Results. linkedin.com/feed/update/ur…

Nidlegy™ Phase III PIVOTAL trial meets the study’s primary objective in patients with locally advanced fully resectable melanoma (Price Sensitive) linkedin.com/feed/update/ur…

Please have a look at the latest article published on s24ore.it/NudmeS via IlSole24ORE about Nidlegy™ Phase 3 trial

Following the announcements of this morning, Philogen management is inviting you to a Webinar on December 5 at 15:00 GMT | 16:00 CET. us06web.zoom.us/webinar/regist…

Excited to announce that Philogen has received the Good Manufacturing Practice Certificate for its Production facility in Rosia (Siena, Italy) by Competent Authorities linkedin.com/feed/update/ur…

Pleased to announce that the Philogen FIBROSARC (NCT04650984) Phase III trial will continue as planned by the protocol following the review of efficacy and safety data in the pre-planned interim analysis by an Independent Data and Safety Monitoring Board. linkedin.com/feed/update/ur…

Philogen is delighted to invite you to attend a virtual briefing on April 3, 2024 (at 10:00 ET / 15:00 BST / 16:00 CET) to discuss the Company’s Full Year 2023 Results. Follow the link below to register to the event or contact us at [email protected]. us06web.zoom.us/webinar/regist…

Don't miss the interview of our CEO Dario Neri on Corriere della Sera!

Philogen is pleased to invite you to a new webinar on October 1, 2024, at 15:00 GMT | 16:00 CET Management will present the financial results and provide an update on the industrial programs. Follow the link to register us06web.zoom.us/webinar/regist…

Sun Pharma and Philogen enter into a global Exclusive Commercialization, License, and Supply Agreement for Commercializing the specialty product FIBROMUN linkedin.com/posts/philogen…

The Board of Directors approves the net financial position of Philogen for the third quarter of 2024 linkedin.com/feed/update/ur…

Philogen is pleased to invite you to a new webinar on December 9, 2024, at 15:00 GMT | 16:00 CET Please contact us at [email protected] or register to the link us06web.zoom.us/webinar/regist…

Philogen Completes Patient Enrollment of the Phase III FIBROSARC Trial in Soft Tissue Sarcoma linkedin.com/posts/philogen…

Philogen is pleased to invite you to an upcoming webinar on April 2, 2025, at 15:00 GMT | 16:00 CET. Click on the link to register or contact us at [email protected] us06web.zoom.us/webinar/regist…

Philochem AG announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, Bristol Myers Squibb Company, for a potential value of up to $1.35bn plus royalties. linkedin.com/feed/update/ur…

We are pleased to invite you to a webinar with Prof. Dario Neri, taking place today, June 11, at 11:00 ET | 17:00 CET. Please contact us at [email protected] or follow the link to register to the event. us06web.zoom.us/webinar/regist…